Mesoblast Non Recurring from 2010 to 2025

MESO Stock  USD 14.26  0.32  2.30%   
Mesoblast Non Recurring yearly trend continues to be very stable with very little volatility. Non Recurring is likely to drop to about 49.5 M. During the period from 2010 to 2025, Mesoblast Non Recurring quarterly data regression pattern had sample variance of 11.3 T and median of  61,919,000. View All Fundamentals
 
Non Recurring  
First Reported
2010-12-31
Previous Quarter
55.7 M
Current Value
49.5 M
Quarterly Volatility
3.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 24.9 M or Selling General Administrative of 20.5 M, as well as many indicators such as Price To Sales Ratio of 122, Dividend Yield of 0.0 or PTB Ratio of 1.5. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
  
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.06
Quarterly Revenue Growth
(0.41)
Return On Assets
(0.05)
Return On Equity
(0.18)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.